Observational study in Annals of laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Haipin ChenDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0009-0006-0795-4474
Jing MiaoDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0002-2825-0648
Juan LiangDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0003-1112-3025
Jingying ZhangDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0001-7639-3937
Weiqun XuDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0001-5592-9376
Fenying ZhaoDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0001-9164-5952
Diying ShenDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0002-2870-1154
Heping ShenDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0002-8683-7842
Hua SongDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0009-0000-4150-6612
Shengchao WuDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0009-0003-5109-1029
Yongmin TangDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0003-1409-5517
Xiaojun XuDepartment of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.ORCID https://orcid.org/0000-0003-1388-2535
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Background: Measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL) can be detected via next-generation sequencing (NGS) of immunoglobulin (Ig) gene rearrangements, particularly in Ig heavy chain ( Methods: This single-center prospective observational cohort study enrolled 506 pediatric patients newly diagnosed as having B-ALL between 2018 and 2022. NGS was performed on bone marrow samples collected at multiple time points, including the end of induction and consolidation. Results: Unlike Conclusions: Non-specific clones reduce the reliability of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Non-specific Clones Hamper the Reliability of Immunoglobulin Light Chain Gene Rearrangements in Next-Generation Sequencing-Based Measurable Residual Disease Monitoring in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Center Cohort Study. · full record | OpenQuestion